2012 TAG Update
TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.
TAGline Fall 2012
TAG at 20 – Part II: On a Darkling Plain—The Years of Despair; Only Stronger U.S. Leadership Can End the AIDS Epidemic; Cure-Related Research at AIDS 2012; The Future of TB in the United States: Going, or Growing?; Getting to Zero—Join the Movement!; GeneXpert Rapid TB Test Price Reduced in Historic Agreement
Mark Harrington Tribute to Médecins Sans Frontières (MSF)
In 2012, the Fulbright Association presented its J. William Fulbright Prize for International Understanding to Médecins Sans Frontières (MSF); the first time this was awarded to an organization, not an individual. Treatment Action Group’s executive director, Mark Harrington, delivered this…
Washington Call for Access to HCV Diagnostics, Treatment and Care for All!
Letter from TAG and civil society organizations undersigned grassroots civil society groups and non-governmental organizations asking for universal access to HCV voluntary testing and treatment.
HIV i-Base/Treatment Action Group 2012 Pipeline Report Reveals Deep Gaps between Scientific Promise and Program Delivery
On the eve of the XIX International AIDS Conference in Washington, D.C., a new report by HIV i-Base (U.K.) and Treatment Action Group (TAG) (U.S.) reveals the deepening gulf between new scientific advances that make it possible to prevent, treat, and in some cases cure people living with HIV, hepatitis C virus (HCV), and tuberculosis (TB), and access to these where they are most needed.
2012 Pipeline Report
HIV, Hepatitis C Virus (HCV), and Tuberculosis (TB) Drugs, Diagnostics, Vaccines, and Preventive Technologies in Development By Polly Clayden, Simon Collins, Colleen Daniels, Nathan Geffen, Mark Harrington, Richard Jefferys, Coco Jervis, Karyn Kaplan, Erica Lessem, and Tracy Swan.
Access to Hepatitis C Treatment: A Global Movement Gains Momentum
By Tracy Swan Being a person living with HIV/AIDS, hepatitis C, and an injection drug user, I look at my body. People want to treat my virus -- my immune system -- people want to treat my chest -- my…
Two New TAG Publications
Research Funding Gaps Revealed Treatment Action Group has published two new reports on the crisis in national and international funding for scientific research on AIDS, tuberculosis (TB), and viral hepatitis. TB and hepatitis are diseases that affect hundreds of millions…
State AIDS Drug Assistance Program (ADAP) Hepatitis Coverage
Hepatitis C Treatment, Psychiatric Medications (SSRIs), Growth Factors, Hepatitis Vaccines (March 2009) Hepatitis C virus (HCV) is a common and serious comorbidity among HIVpositive people in the United States; up to 30%—approximately 332,000— are living with HCV. Hepatitis C can…
A Delicate Balance: Accelerated Approval and Postmarketing Commitments
Research presentation poster by Tracy Swan and Lei Chou; winner of a Chairman’s Choice Award at the 2008 HIV DART conference “Frontiers in Drug Development for Antiretroviral Therapies.” The complete text is available online. Populations in Preapproval Studies and…
